Overall, these comprehensive findings unequivocally show the clinical utility of Tirzepatide which will help all diabetes stakeholders in their decision-making, particularly in comparison with other injectables such as GLP-1 RA (weekly) or insulin preparations (daily) in T2DM patients. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.